Information Provided By:
News For JBHT From the Last 2 Days
JBHT
Jul 16, 2019 | 16:32 EDT
The major averages were mixed and searching for direction for much of the morning, though stocks picked up some downward momentum after President Trump told reporters at the White House, according to CNBC, that a trade deal with China has "a long way to go. " The president... To see the rest of the story go to thefly.com. See Story Here
JBHT
Jul 16, 2019 | 08:59 EDT
UP AFTER EARNINGS: Goldman Sachs (GS), up 1%... First Horizon (FHN), up 4%... J.B. Hunt (JBHT), up 7%. ALSO HIGHER: Melinta Therapeutics (MLNT), up 8% after the FDA accepted a supplemental new drug application for Baxdela for priority review and reporting preliminary Q2 net product sales of approximately $13.8M. DOWN AFTER EARNINGS: JPMorgan (JPM), down 2%... Wells Fargo (WFC), down 1%... Domino's Pizza (DPZ), down 7%. ALSO LOWER: Cognex (CGNX), down 4% after Goldman Sachs analyst Joseph Ritchie downgraded shares to Sell from Neutral and lowered his price target for the shares to $36 from $45. The analyst shuffled his ratings in the Americas Multi-Industry ahead of the Q2 earnings season. He sees a "rocky road ahead."... Qutoutiao (QTT), down 9% after announcing that, in compliance with recent regulatory requirements, from July 16 to October 15, Midu Novels will undergo product upgrades and temporarily suspend content updates and certain commercial activities... Medical Properties Trust (MPW), down 4% after a 45M share spot secondary priced at $17.29.
JBHT
Jul 16, 2019 | 07:40 EDT
Susquehanna analyst Bascome Majors raised his price target on J.B. Hunt to $114 from $110 following Q2 earnings. The analyst said the considerable upside core profit in Dedicated and a better than feared bottom line and outlook in Intermodal suggests near-term expectations shot to the downside. Major reiterated his Positive rating on J.B. Hunt shares.
JBHT
Jul 16, 2019 | 07:19 EDT
Stephens analyst Justin Long said investor sentiment was "very negative" going into J.B. Hunt's Q2 report and he thinks results were clearly "better than feared." The primary upside drivers were the dedicated and intermodal segments, partially offset by a weaker than expected performance in the brokerage segment, noted Long, who expects the stock to move higher on the heels of this report. While he still sees a heightened level of uncertainty around the freight cycle, Long continues to view J.B. Hunt as well-positioned over the long-term. He raised his price target on the shares to $110 from $107 and keeps an Overweight rating on the stock.
JBHT
Jul 15, 2019 | 18:58 EDT
UP AFTER EARNINGS: JB Hunt (JBHT) up 7.1%. ALSO HIGHER: Eyenovia (EYEN) up 6.0% after disclosing CEO bought 234K shares of stock... Viking Therapeutics (VKTX) up 1.2% after being initiated with Outperform at Oppenheimer. DOWN AFTER EARNINGS: Arrow Electronics (ARW) down 5.3% after below-consensus Q2 pre-announcement. ALSO LOWER: Anterix (ATEX) down 6.0% after equity offering... Repligen (RGEN) down 3.4% after equity offering... Medical Properties Trust (MPW) down 3.2% after equity offering. Movers as of 18:30ET.
JBHT
Jul 15, 2019 | 16:04 EDT
Reports Q2 Intermodal operating income $124.4M, down 7% from last year. Reports Q2 intermodal load volumes down 8%.
JBHT
Jul 15, 2019 | 14:52 EDT
Notable companies reporting after the market close, with earnings consensus, include J.B. Hunt (JBHT), consensus $1.35.
JBHT
Jul 15, 2019 | 14:49 EDT
Pre-earnings options volume in J B Hunt Transport Services is 5.3x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 7.0%, or $6.44, after results are released. Median move over the past eight quarters is 1.9%.